Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register

Voluntary Licensing in Pharma: How Generic Makers Win Royalty-Free Licences

Mitul Agarwal
Written by Mitul Agarwal · B.Pharm, MBA
Founder & Head of Business Development · 25+ years in international pharmaceutical BD&L
Published 21 November 2026
Voluntary Licensing in Pharma: How Generic Makers Win Royalty-Free Licences

By the PharmaTradz BD Team. Published November 2026.

In short: Originators increasingly grant royalty-free voluntary licences so generic manufacturers can supply low- and middle-income countries quickly, often before a medicine is even approved. In November 2026 the developer of the antiviral obeldesivir licensed three generic manufacturers for 127 countries. Manufacturers who want to be chosen next need quality systems that pass stringent or WHO review, reliable API supply and a track record in the markets covered.

Voluntary licensing used to be associated mainly with HIV medicines. Today it is becoming a standard part of how innovators respond to outbreaks and how they plan access in poorer markets. For generic manufacturers, it is one of the few ways to supply a new molecule years before patents expire. For distributors and tender suppliers in Africa, Asia and Latin America, it is often the route by which affordable versions first reach their markets.

What happened this month

On 16 November 2026, the developer of obeldesivir, an investigational oral antiviral, announced royalty-free voluntary licences with three generic manufacturers based in India, Egypt and Pakistan, with more under discussion. The licences cover 127 mainly low- and lower-middle-income countries, including all African countries that have reported cases in the current Ebola Bundibugyo outbreak, the same territory as the company's earlier remdesivir licences.

Two details matter. First, obeldesivir is not yet approved for this use anywhere; it is being tested as post-exposure prophylaxis in a Phase 3 trial. Licensees may supply it only if clinical data and regulatory authorisations support it. Second, the licences are designed to prepare manufacturing before the evidence is in, so that supply is ready if the trial succeeds (Pharmaceutical Executive).

How voluntary licences usually work

  • Territory. A defined list of countries, usually low- and lower-middle-income, sometimes some upper-middle-income markets. High-income markets stay with the originator.
  • Royalties. Often zero during an emergency or in the poorest countries, sometimes a small percentage elsewhere.
  • Technology transfer. Some licences include know-how and process documents; others only grant patent rights, leaving the generic maker to develop the process.
  • Quality conditions. Licensees are commonly expected to meet WHO prequalification or approval by a stringent regulatory authority before supplying donor-funded programmes.
  • Intermediaries. Some licences are negotiated directly; others go through the Medicines Patent Pool, which then sub-licenses to several generic manufacturers.

What originators look for in a licensee

Licensees are chosen, not appointed by lottery. From the deals we have seen, originators and pools look for:

  1. Proven quality. WHO-prequalified products or approvals from stringent regulators, and clean recent inspections.
  2. API capability. In-house synthesis or a secure API partner, because a licence is worthless if the API cannot be made at scale.
  3. Speed. The ability to file and supply quickly in the licensed territory, often in parallel in several countries.
  4. Market reach. Registrations, distributors and tender experience across Africa, Asia and Latin America.
  5. Affordable pricing. A credible commitment to low prices for public programmes.

What it means for distributors and tender suppliers

When licensed generics reach WHO prequalification, they usually enter donor-funded and national tenders first. Distributors who already hold relationships with likely licensees, and who track special-import and emergency tenders, are best placed to supply. In outbreaks, importing before local registration is often possible through emergency-use or special-import routes, so keeping the regulatory paperwork ready matters as much as price.

Our view

We see voluntary licensing moving from exception to expectation. Originators face pressure from governments and funders to show an access plan, and licensing a handful of capable generic manufacturers is the fastest, most credible answer. The obeldesivir deal shows a further shift: licences are now signed before approval, so manufacturing capacity is ready the day the evidence arrives.

For generic manufacturers, this rewards preparation. Companies that maintain WHO-prequalified or stringently approved portfolios, keep spare sterile and oral capacity, and have regulatory teams familiar with emergency pathways will keep being chosen. Companies that compete only on price in their home market will not. Our advice is to build a "licence-ready" profile now, rather than waiting for the next outbreak to start the conversation.

Practical steps

  1. Track new voluntary licences and Medicines Patent Pool calls for expressions of interest.
  2. Prioritise WHO prequalification for at least one product in each key therapeutic area.
  3. Secure API supply for antivirals and anti-infectives that are likely licensing candidates.
  4. Build distributor partnerships in the licensed territories before a licence is granted.

Related reading on PharmaTradz

The bottom line

Voluntary licences are becoming the main route by which new antivirals and anti-infectives reach lower-income markets. The manufacturers that get licensed are the ones that were already ready.

This article is general business information, not legal or medical advice. Licence terms and regulatory requirements differ; check the details with the licensor, the relevant authority or a qualified adviser.


Frequently Asked Questions(FAQs)

What is a voluntary licence in pharma?

An agreement in which a patent holder lets generic manufacturers make and sell its medicine in defined countries, usually low- and middle-income markets, often royalty-free or at low royalties.

What did the obeldesivir licensing deal include?

In November 2026 the developer granted royalty-free licences to three generic manufacturers for 127 mainly low- and lower-middle-income countries. Supply depends on clinical data and regulatory authorisation, since the use is still investigational.

How does the Medicines Patent Pool fit in?

The Medicines Patent Pool negotiates licences with originators and then sub-licenses several generic manufacturers, which speeds up competition and access in the covered countries.

What do originators look for in a licensee?

Proven quality (WHO prequalification or stringent approvals), secure API supply, fast regulatory filing, distribution reach in the licensed territory and a commitment to affordable prices.

Can distributors benefit from voluntary licences?

Yes. Licensed generics usually enter donor-funded and national tenders first, so distributors with ties to licensees and experience with emergency and special-import routes are well placed to supply.

Disclaimer: The information presented in this article is for informational and educational purposes only. While every effort has been made to ensure data accuracy and reliability, readers are advised to independently verify all figures, regulations, and market insights before making any business or investment decisions.

Category: Pharma Blogs

← Back to All Articles

 

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.
WhatsApp us